GlaxoSmithKline And Theravance Announce Start Of Large Phase 2B ICS And LABA Studies For Asthma In The Horizon Program

GlaxoSmithKline (NYSE: GSK) and Theravance, Inc. (Nasdaq: THRX) announced the start of large Phase 2b asthma dose-optimization studies with both the lead inhaled corticosteroid (ICS) GW685698 (’698) and the lead long-acting beta agonist (LABA) GW642444 (’444) assets in the ‘Horizon’ program to develop a next-generation combination product.

More: continued here

Filed under: Clinical Trials on January 4th, 2008